Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Castle Biosciences Inc

Healthcare US CSTL

21.01USD
-0.59(2.73%)

Last update at 2026-06-05T20:00:00Z

Day Range

20.9921.78
LowHigh

52 Week Range

14.5944.28
LowHigh

Fundamentals

  • Previous Close 21.60
  • Market Cap744.67M
  • Volume212464
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.03900M
  • Revenue TTM344.23M
  • Revenue Per Share TTM11.88
  • Gross Profit TTM 273.20M
  • Diluted EPS TTM-0.83

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -29.51400M 21.56M -57.36500M -68.90400M -40.01200M
Minority interest - - - - -
Net income -24.15800M 18.25M -57.46600M -67.13800M -31.29200M
Selling general administrative 229.32M 76.58M 66.50M 143.00M 86.74M
Selling and marketing expenses - 123.47M 113.66M - -
Gross profit 236.35M 271.86M 174.81M 105.03M 78.26M
Reconciled depreciation 40.77M 16.00M 11.95M 10.54M 3.41M
Ebit -29.42800M 22.14M -57.35400M -91.14200M -40.07900M
Ebitda 11.34M 38.14M -45.02400M -76.63100M -36.60400M
Depreciation and amortization 40.77M 16.00M 12.33M 14.51M 3.48M
Non operating income net other - - - - -
Operating income -42.81000M 8.67M -67.97700M -91.14200M -40.07900M
Other operating expenses 387.04M 323.40M 287.76M 228.18M 134.16M
Interest expense 0.09M 0.58M 0.01M 0.02M 0.00100M
Tax provision -5.35600M 3.32M 0.12M -1.76600M -8.72000M
Interest income 11.77M 12.92M 9.78M 3.97M 0.07M
Net interest income 11.69M 12.34M 9.77M 3.95M 0.07M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.35600M 3.32M 0.10M -1.76600M -8.72000M
Total revenue 344.23M 332.07M 219.79M 137.04M 94.08M
Total operating expenses 279.16M 263.19M 242.78M 196.17M 118.34M
Cost of revenue 107.88M 60.20M 44.98M 32.01M 15.82M
Total other income expense net 13.30M 12.89M 10.61M 22.24M 0.07M
Discontinued operations - - - - -
Net income from continuing ops -24.15800M 18.25M -75.50400M -67.13800M -31.29200M
Net income applicable to common shares - - - -67.13800M -31.29200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 578.56M 531.24M 477.81M 447.33M 462.57M
Intangible assets 88.88M 95.54M 106.64M 115.66M 88.92M
Earning assets - - - - -
Other current assets 7.96M 7.67M 6.29M 6.21M 4.81M
Total liab 107.68M 75.40M 86.54M 48.18M 50.83M
Total stockholder equity 470.87M 455.83M 391.27M 399.15M 411.74M
Deferred long term liab - - - - -
Other current liab 48.22M 39.47M 36.26M 29.62M 21.16M
Common stock 0.03M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.03M 0.03M 0.03M 0.03M 0.03M
Retained earnings -224.28400M -200.12600M -218.37100M -160.90500M -93.76700M
Other liab - - - 0.43M 19.05M
Good will 99.57M 10.69M 10.69M 10.69M -
Other assets - - - 2.20M 3.02M
Cash 116.73M 119.71M 98.84M 122.95M 329.63M
Cash and equivalents - - - - -
Total current liabilities 68.68M 49.39M 47.67M 36.13M 24.89M
Current deferred revenue - - - - -
Net debt -79.81600M -93.36500M -83.53100M -109.63800M -321.55400M
Short term debt 1.74M 1.94M 1.14M 1.78M 1.18M
Short long term debt 0.42M 0.28M - - -
Short long term debt total 36.91M 26.34M 15.31M 13.31M 8.08M
Other stockholder equity 694.86M 655.70M 609.48M 560.41M 505.48M
Property plant equipment - - - 26.50M 16.88M
Total current assets 361.10M 360.15M 295.63M 292.29M 353.74M
Long term investments - - - - -
Net tangible assets - - - 272.80M 322.82M
Short term investments 182.78M 173.42M 144.26M 135.68M -
Net receivables 43.38M 51.22M 38.30M 23.48M 17.28M
Long term debt 9.64M 9.74M - - -
Inventory 10.25M 8.13M 7.94M 3.98M 2.02M
Accounts payable 18.71M 6.90M 10.27M 4.73M 2.55M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.27M 0.23M 0.14M -0.38100M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.65M 2.15M 1.44M 2.20M 3.02M
Deferred long term asset charges - - - - -
Non current assets total 217.46M 171.08M 182.18M 155.04M 108.83M
Capital lease obligations 26.86M 16.32M 15.34M 13.31M 8.08M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 2.02M -50.13700M -12.99300M -166.54500M -66.65700M
Change to liabilities - - - 0.58M -0.18200M
Total cashflows from investing activities -60.36700M -50.13700M -16.18300M -166.54500M -66.65700M
Net borrowings 0.07M 9.90M -0.14200M -0.12200M -0.00800M
Total cash from financing activities -6.96000M 6.14M -2.29800M 1.51M 5.42M
Change to operating activities - - - 7.31M 0.38M
Net income -24.15800M 18.25M -57.46600M -67.13800M -31.29200M
Change in cash -2.98000M 20.87M -24.10700M -206.68500M -80.21900M
Begin period cash flow 119.71M 98.84M 122.95M 329.63M 409.85M
End period cash flow 116.73M 119.71M 98.84M 122.95M 329.63M
Total cash from operating activities 64.35M 64.87M -5.62600M -41.65500M -18.98300M
Issuance of capital stock - - - - 0.00000M
Depreciation 40.77M 16.00M 12.33M 10.54M 3.41M
Other cashflows from investing activities -7.63800M 0.02M 0.01M - -
Dividends paid - - - - -
Change to inventory -2.14200M -0.19300M -3.96200M -1.68000M 0.33M
Change to account receivables 6.88M -12.64300M -14.93000M -6.21800M -4.63100M
Sale purchase of stock - - -5.13400M - -
Other cashflows from financing activities -9.05100M -5.78100M -2.15600M 0.80M 5.43M
Change to netincome - - - 14.95M 13.00M
Capital expenditures 36.02M 28.33M 13.62M 5.63M 3.48M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 13.60M -14.12500M -6.63000M -0.00700M -4.10200M
Stock based compensation 45.89M 50.32M 51.22M 36.32M 21.74M
Other non cash items -5.53200M -6.97200M -4.85600M -19.49700M 75.76M
Free cash flow 28.33M 36.54M -19.24700M -47.28700M -22.46600M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CSTL
Castle Biosciences Inc		 -0.59 2.73% 21.01 - - 2.16 1.62 1.45 44.10
TMO
Thermo Fisher Scientific Inc		 -9.23 1.91% 472.80 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -2.34 1.25% 184.30 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -2.93 2.12% 135.44 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -2.58 0.46% 562.16 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Castle Biosciences Inc

1500 W. Parkwood Ave, Friendswood, TX, United States, 77546

Key Executives

Name Title Year Born
Mr. Derek J. Maetzold Founder, CEO, Pres & Director 1962
Mr. Frank Stokes CFO & Treasurer 1970
Ms. Kristen M. Oelschlager R.N., RN Chief Operating Officer 1968
Mr. Toby W. Juvenal Chief Commercial Officer 1961
Camilla Zuckero Exec. Director of Investor Relations & Corp. Communications NA
Ms. Alice Bahner Izzo Sr. VP of Marketing NA
Ms. Keli Greenberg VP of HR & Exec. Director of HR NA
Dr. Robert W. Cook Ph.D. Sr. VP of R&D 1972
Mr. Bernhard E. Spiess Company Sec. 1960
Mr. John W. Abbott VP & Controller NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.